Trial watch: anticancer vaccination with dendritic cells

Trial watch: anticancer vaccination with dendritic cells

Dendritic cells (DCs) are critical players at the intersection of innate and adaptive immunity, making them ideal candidates for anticancer vaccine development. DC-based immunotherapies typically involve isolating patient-derived DCs, pulsing them with tumor-associated antigens (TAAs) or tumor-speci...

Full description

Saved in:
Bibliographic Details
Main Authors: Francisca Borges, Raquel S. Laureano, Isaure Vanmeerbeek, Jenny Sprooten, Octavie Demeulenaere, Jannes Govaerts, Lisa Kinget, Saurabh Saraswat, Benoit Beuselinck, Steven De Vleeschouwer, Paul Clement, Frederik De Smet, Rüdiger V. Sorg, Angeliki Datsi, Nathalie Vigneron, Stefan Naulaerts, Abhishek D. Garg
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Antigen cross-presentation
clinical trial
DAMPs
dendritic cells
immune checkpoint blockers
T cell priming
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2024.2412876
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items